Biogen Prices Drug for Deadly Muscle Disease At $375,000 a Year

Biogen Inc. will charge $375,000 a year for its drug for a rare and deadly muscle disease, a sign that drugmakers can still command high prices for products that treat conditions where patients have few if any other options.

The therapy for spinal muscular atrophy, called Spinraza, will have a list price of $125,000 a vial, a Biogen spokesman said Dec. 28 by phone. The drug will cost $750,000 for the first 12 months of treatment because patients take twice as many doses during that year.

Developed with Ionis Pharmaceuticals Inc. and approved Dec. 23 by U.S. regulators, Spinraza is Biogen’s most important new ...